JP2009537517A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009537517A5 JP2009537517A5 JP2009510923A JP2009510923A JP2009537517A5 JP 2009537517 A5 JP2009537517 A5 JP 2009537517A5 JP 2009510923 A JP2009510923 A JP 2009510923A JP 2009510923 A JP2009510923 A JP 2009510923A JP 2009537517 A5 JP2009537517 A5 JP 2009537517A5
- Authority
- JP
- Japan
- Prior art keywords
- furo
- azabicyclo
- spiro
- octane
- furyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229910052757 nitrogen Inorganic materials 0.000 claims 12
- 150000003839 salts Chemical class 0.000 claims 12
- 150000001875 compounds Chemical class 0.000 claims 9
- 235000010299 hexamethylene tetramine Nutrition 0.000 claims 9
- 229960004011 methenamine Drugs 0.000 claims 9
- 238000001727 in vivo Methods 0.000 claims 7
- 239000002243 precursor Substances 0.000 claims 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 5
- 229910052739 hydrogen Inorganic materials 0.000 claims 5
- 239000001257 hydrogen Substances 0.000 claims 5
- 229910052760 oxygen Inorganic materials 0.000 claims 5
- 229910052717 sulfur Inorganic materials 0.000 claims 5
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims 3
- 125000000217 alkyl group Chemical group 0.000 claims 3
- 206010057852 Nicotine dependence Diseases 0.000 claims 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 125000002541 furyl group Chemical group 0.000 claims 2
- 125000005842 heteroatom Chemical group 0.000 claims 2
- 125000000623 heterocyclic group Chemical group 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 125000002757 morpholinyl group Chemical group 0.000 claims 2
- 239000001301 oxygen Chemical group 0.000 claims 2
- 125000004193 piperazinyl group Chemical group 0.000 claims 2
- 125000003386 piperidinyl group Chemical group 0.000 claims 2
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 2
- 125000006413 ring segment Chemical group 0.000 claims 2
- 239000011593 sulfur Chemical group 0.000 claims 2
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 claims 1
- IHIIIDMMCFNRSA-QFIPXVFZSA-N (3r)-5'-[5-(morpholin-4-ylmethyl)furan-2-yl]spiro[1-azabicyclo[2.2.2]octane-3,2'-3h-furo[2,3-b]pyridine] Chemical compound C=1C=C(C=2C=C3C[C@@]4(OC3=NC=2)C2CCN(CC2)C4)OC=1CN1CCOCC1 IHIIIDMMCFNRSA-QFIPXVFZSA-N 0.000 claims 1
- PFXZDYFCWCJPGP-QFIPXVFZSA-N (3r)-5'-[5-(morpholin-4-ylmethyl)furan-3-yl]spiro[1-azabicyclo[2.2.2]octane-3,2'-3h-furo[2,3-b]pyridine] Chemical compound C=1C(C=2C=C3C[C@@]4(OC3=NC=2)C2CCN(CC2)C4)=COC=1CN1CCOCC1 PFXZDYFCWCJPGP-QFIPXVFZSA-N 0.000 claims 1
- KQPRBJVDAZZSAU-QFIPXVFZSA-N (3r)-5'-[5-(pyrrolidin-1-ylmethyl)furan-2-yl]spiro[1-azabicyclo[2.2.2]octane-3,2'-3h-furo[2,3-b]pyridine] Chemical compound C=1C=C(C=2C=C3C[C@@]4(OC3=NC=2)C2CCN(CC2)C4)OC=1CN1CCCC1 KQPRBJVDAZZSAU-QFIPXVFZSA-N 0.000 claims 1
- VIJLMJSMFUQJTO-QFIPXVFZSA-N (3r)-5'-[5-(pyrrolidin-1-ylmethyl)furan-3-yl]spiro[1-azabicyclo[2.2.2]octane-3,2'-3h-furo[2,3-b]pyridine] Chemical compound C=1C(C=2C=C3C[C@@]4(OC3=NC=2)C2CCN(CC2)C4)=COC=1CN1CCCC1 VIJLMJSMFUQJTO-QFIPXVFZSA-N 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 208000000044 Amnesia Diseases 0.000 claims 1
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims 1
- 208000020925 Bipolar disease Diseases 0.000 claims 1
- 208000019888 Circadian rhythm sleep disease Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 201000004311 Gilles de la Tourette syndrome Diseases 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 201000006347 Intellectual Disability Diseases 0.000 claims 1
- 208000001456 Jet Lag Syndrome Diseases 0.000 claims 1
- 208000020358 Learning disease Diseases 0.000 claims 1
- 206010026749 Mania Diseases 0.000 claims 1
- 208000026139 Memory disease Diseases 0.000 claims 1
- 208000012902 Nervous system disease Diseases 0.000 claims 1
- 102000019315 Nicotinic acetylcholine receptors Human genes 0.000 claims 1
- 108050006807 Nicotinic acetylcholine receptors Proteins 0.000 claims 1
- 208000002193 Pain Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 208000025569 Tobacco Use disease Diseases 0.000 claims 1
- 208000000323 Tourette Syndrome Diseases 0.000 claims 1
- 208000016620 Tourette disease Diseases 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 125000003342 alkenyl group Chemical group 0.000 claims 1
- 125000000304 alkynyl group Chemical group 0.000 claims 1
- 230000036506 anxiety Effects 0.000 claims 1
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims 1
- 230000009286 beneficial effect Effects 0.000 claims 1
- 208000028683 bipolar I disease Diseases 0.000 claims 1
- 230000001713 cholinergic effect Effects 0.000 claims 1
- 230000007278 cognition impairment Effects 0.000 claims 1
- 235000019788 craving Nutrition 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 230000007812 deficiency Effects 0.000 claims 1
- 230000006735 deficit Effects 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- 125000001072 heteroaryl group Chemical group 0.000 claims 1
- 208000033915 jet lag type circadian rhythm sleep disease Diseases 0.000 claims 1
- 201000003723 learning disability Diseases 0.000 claims 1
- 239000000314 lubricant Substances 0.000 claims 1
- 230000006984 memory degeneration Effects 0.000 claims 1
- 208000023060 memory loss Diseases 0.000 claims 1
- ZFLIWLTZPYHUBM-IBGZPJMESA-N n-methyl-1-[5-[(3r)-spiro[1-azabicyclo[2.2.2]octane-3,2'-3h-furo[2,3-b]pyridine]-5'-yl]thiophen-2-yl]methanamine Chemical compound S1C(CNC)=CC=C1C1=CN=C(O[C@]2(C3)C4CCN(CC4)C2)C3=C1 ZFLIWLTZPYHUBM-IBGZPJMESA-N 0.000 claims 1
- UBBPGHMTJPPULM-QFIPXVFZSA-N n-methyl-n-[[4-[(3r)-spiro[1-azabicyclo[2.2.2]octane-3,2'-3h-furo[2,3-b]pyridine]-5'-yl]furan-2-yl]methyl]cyclopropanamine Chemical compound C=1C(C=2C=C3C[C@@]4(OC3=NC=2)C2CCN(CC2)C4)=COC=1CN(C)C1CC1 UBBPGHMTJPPULM-QFIPXVFZSA-N 0.000 claims 1
- YICKPQPPCVYQKE-QFIPXVFZSA-N n-methyl-n-[[5-[(3r)-spiro[1-azabicyclo[2.2.2]octane-3,2'-3h-furo[2,3-b]pyridine]-5'-yl]furan-2-yl]methyl]cyclopropanamine Chemical compound C=1C=C(C=2C=C3C[C@@]4(OC3=NC=2)C2CCN(CC2)C4)OC=1CN(C)C1CC1 YICKPQPPCVYQKE-QFIPXVFZSA-N 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 229960002715 nicotine Drugs 0.000 claims 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 208000020016 psychiatric disease Diseases 0.000 claims 1
- 201000000980 schizophrenia Diseases 0.000 claims 1
- 230000005586 smoking cessation Effects 0.000 claims 1
- 230000000946 synaptic effect Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US74747606P | 2006-05-17 | 2006-05-17 | |
| US82497506P | 2006-09-08 | 2006-09-08 | |
| PCT/SE2007/000485 WO2007133155A1 (en) | 2006-05-17 | 2007-05-16 | Nicotinic acetylcholine receptor ligands 101 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009537517A JP2009537517A (ja) | 2009-10-29 |
| JP2009537517A5 true JP2009537517A5 (https=) | 2010-04-02 |
Family
ID=38694158
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009510923A Pending JP2009537517A (ja) | 2006-05-17 | 2007-05-16 | ニコチン性アセチルコリン受容体リガンド１０１ |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US7842803B2 (https=) |
| EP (1) | EP2019831B1 (https=) |
| JP (1) | JP2009537517A (https=) |
| KR (1) | KR20090007753A (https=) |
| AR (1) | AR060914A1 (https=) |
| AU (1) | AU2007250560B2 (https=) |
| BR (1) | BRPI0711941A2 (https=) |
| CA (1) | CA2652610A1 (https=) |
| CL (1) | CL2007001405A1 (https=) |
| EC (1) | ECSP088971A (https=) |
| ES (1) | ES2392997T3 (https=) |
| IL (1) | IL195019A0 (https=) |
| MX (1) | MX2008014436A (https=) |
| NO (1) | NO20084915L (https=) |
| RU (1) | RU2441007C2 (https=) |
| SA (1) | SA07280244B1 (https=) |
| TW (1) | TW200813067A (https=) |
| UY (1) | UY30349A1 (https=) |
| WO (1) | WO2007133155A1 (https=) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0220581D0 (en) | 2002-09-04 | 2002-10-09 | Novartis Ag | Organic Compound |
| PE20060437A1 (es) | 2004-06-18 | 2006-06-08 | Novartis Ag | COMPUESTOS AZA-BICICLONONANOS COMO LIGANDOS COLINERGICOS DE nAChR |
| GB0415746D0 (en) | 2004-07-14 | 2004-08-18 | Novartis Ag | Organic compounds |
| GB0521508D0 (en) | 2005-10-21 | 2005-11-30 | Novartis Ag | Organic compounds |
| GB0525673D0 (en) | 2005-12-16 | 2006-01-25 | Novartis Ag | Organic compounds |
| GB0525672D0 (en) | 2005-12-16 | 2006-01-25 | Novartis Ag | Organic compounds |
| WO2009066107A1 (en) * | 2007-11-21 | 2009-05-28 | Astrazeneca Ab | Use of a nicotinic receptor agonist |
| JO3250B1 (ar) | 2009-09-22 | 2018-09-16 | Novartis Ag | إستعمال منشطات مستقبل نيكوتينيك أسيتيل كولين ألفا 7 |
| KR20140003580A (ko) | 2011-01-27 | 2014-01-09 | 노파르티스 아게 | 니코틴성 아세틸콜린 수용체 알파 7 활성화제의 용도 |
| WO2012127393A1 (en) | 2011-03-18 | 2012-09-27 | Novartis Ag | COMBINATIONS OF ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVATORS AND mGluR5 ANTAGONISTS FOR USE IN DOPAMINE INDUCED DYSKINESIA IN PARKINSON'S DISEASE |
| JP6162705B2 (ja) | 2011-10-20 | 2017-07-12 | ノバルティス アーゲー | アルファ７ニコチン性アセチルコリン受容体活性化剤による処置に対する応答性を予測するバイオマーカー |
| KR102043309B1 (ko) | 2012-12-11 | 2019-11-11 | 노파르티스 아게 | 알파 7 니코틴성 아세틸콜린 수용체 활성화제 치료에 대한 반응성의 예측 바이오마커 |
| CN105263492B (zh) | 2013-01-15 | 2018-04-10 | 诺华有限公司 | α7烟碱型乙酰胆碱受体激动剂在治疗发作性睡病中的应用 |
| BR112015016992A8 (pt) | 2013-01-15 | 2018-01-23 | Novartis Ag | uso de agonistas do receptor alfa 7 nicotínico de acetilcolina |
| EP2945633B1 (en) | 2013-01-15 | 2021-06-30 | Novartis AG | Use of alpha 7 nicotinic acetylcholine receptor agonists |
| US11209254B2 (en) * | 2016-03-09 | 2021-12-28 | Msato, Llc | Pellet shaped marking round for air rifles and pistols |
| HU231333B1 (hu) * | 2018-07-13 | 2023-01-28 | Richter Gedeon Nyrt | Spirokromán származékok |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR013184A1 (es) * | 1997-07-18 | 2000-12-13 | Astrazeneca Ab | Aminas heterociclicas espiroazobiciclicas, composicion farmaceutica, uso de dichas aminas para preparar medicamentos y metodo de tratamiento o profilaxis |
| DE60218032T2 (de) * | 2001-06-01 | 2007-08-16 | Astrazeneca Ab | Neuer, für die therapie geeigneter ligand für nikotinische acetylcholinrezeptoren |
| BR0309342A (pt) * | 2002-04-18 | 2005-02-15 | Astrazeneca Ab | Composto, composição farmacêutica, uso de um composto, e, método de tratamento ou profilaxia de doenças ou condições humanas |
| US7417050B2 (en) * | 2002-04-18 | 2008-08-26 | Astrazeneca Ab | Heterocyclic compounds |
| EP1499618B1 (en) * | 2002-04-18 | 2010-10-13 | AstraZeneca AB | Furyl compounds |
| WO2005030778A1 (en) * | 2003-09-25 | 2005-04-07 | Astrazeneca Ab | Ligands |
-
2007
- 2007-05-10 TW TW096116654A patent/TW200813067A/zh unknown
- 2007-05-14 AR ARP070102066A patent/AR060914A1/es not_active Application Discontinuation
- 2007-05-14 SA SA07280244A patent/SA07280244B1/ar unknown
- 2007-05-15 UY UY30349A patent/UY30349A1/es not_active Application Discontinuation
- 2007-05-16 KR KR1020087027857A patent/KR20090007753A/ko not_active Abandoned
- 2007-05-16 CA CA002652610A patent/CA2652610A1/en not_active Abandoned
- 2007-05-16 EP EP07748149A patent/EP2019831B1/en active Active
- 2007-05-16 JP JP2009510923A patent/JP2009537517A/ja active Pending
- 2007-05-16 MX MX2008014436A patent/MX2008014436A/es not_active Application Discontinuation
- 2007-05-16 BR BRPI0711941-0A patent/BRPI0711941A2/pt not_active IP Right Cessation
- 2007-05-16 AU AU2007250560A patent/AU2007250560B2/en not_active Ceased
- 2007-05-16 RU RU2008143450/04A patent/RU2441007C2/ru not_active IP Right Cessation
- 2007-05-16 CL CL2007001405A patent/CL2007001405A1/es unknown
- 2007-05-16 ES ES07748149T patent/ES2392997T3/es active Active
- 2007-05-16 WO PCT/SE2007/000485 patent/WO2007133155A1/en not_active Ceased
- 2007-05-17 US US11/749,820 patent/US7842803B2/en active Active
-
2008
- 2008-10-30 IL IL195019A patent/IL195019A0/en unknown
- 2008-11-21 NO NO20084915A patent/NO20084915L/no not_active Application Discontinuation
- 2008-12-12 EC EC2008008971A patent/ECSP088971A/es unknown
-
2010
- 2010-11-05 US US12/940,449 patent/US20110136804A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009537517A5 (https=) | ||
| RU2008143450A (ru) | Лиганды никотиновых ацетилхолиновых рецепторов 101 | |
| JP6994474B2 (ja) | Ｓｈｐ２の活性を阻害するための化合物および組成物 | |
| RU2653054C2 (ru) | Замещенные соединения пиридин азолопиримидин-5-(6н)-она | |
| JP2005527588A5 (https=) | ||
| JP2013516393A5 (https=) | ||
| NZ592275A (en) | Spiro-oxindole compounds and their use as therapeutic agents | |
| FI2534153T4 (fi) | 8-fluori-2-{4-[(metyyliamino}metyyli]fenyyli}-1,3,4,5-tetrahydro-6h-atsepino[5,4,3-cd]indol-6-onin suoloja ja polymorfeja | |
| JP2013539789A5 (https=) | ||
| JP2014513140A5 (https=) | ||
| RU99128075A (ru) | Производные 8-азабицикло(3,2,1)окт-2-ена и-октана в качестве холинергических лигандов на ацх-рецепторах | |
| CA2851151A1 (en) | Aminoquinazoline derivatives and their salts and methods of use | |
| IL276292B1 (en) | CSF–1R receptor antagonists | |
| JP2018514552A5 (https=) | ||
| JP2018501315A5 (https=) | ||
| JP2018513191A5 (https=) | ||
| RU2012112064A (ru) | Положительные аллостерические модуляторы м1-рецепторов на основе пираниларилметилбензохиназолинона | |
| CA3085255A1 (en) | Eif4e-inhibiting compounds and methods | |
| EP3185865A1 (en) | TETRAHYDRONAPHTHYRIDINE DERIVATIVES AS mGluR2-NEGATIVE ALLOSTERIC MODULATORS, COMPOSITIONS, AND THEIR USE | |
| ES2837018T3 (es) | Ligandos del receptor D3 de dopamina de 6,7,8,9-tetrahidro-5H-pirido[2,3-d]azepina | |
| RU2016116777A (ru) | Комбинированная терапия с использованием азабициклосоединения для ракового заболевания | |
| EP3965766A1 (en) | Combination of an ?2-adrenoceptor subtype c (alpha-2c) antagonists with a task1/3 channel blocker for the treatment of sleep apnea | |
| JP2007515479A5 (https=) | ||
| WO2023107714A2 (en) | Methods for treating neurological disorders | |
| WO2009082698A1 (en) | Compositions for treatment of cognitive disorders |